Publications
Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn’s disease
Citation
Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Aliment Pharmacol Ther. 2018 Jul;48(2):114-126. doi: 10.1111/apt.14821. Epub 2018 May 30. PMID: 29851091.
Abstract
Background: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn’s disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial.